

2019 EMERGING THERAPIES FOR PBC, NASH, ESLD AND HCC SEMINAR SERIES

Palo Alto, CA – March 16, 2019

Conference Location **Sheraton Palo Alto** **Phone:** (650) 328-2800
625 El Camino Real
Palo Alto CA 94301
<https://www.marriott.com/hotels/travel/sjcsi-sheraton-palo-alto-hotel>

Parking at the Conference Complimentary Parking has been arranged for program participants
Once you enter the self-parking area, bring the parking ticket to the Seminar Registration Desk

Driving Directions

- **From San Francisco** – Take Highway 101 South and exit onto Embarcadero Road West. Proceed approximately two miles and turn right onto El Camino Real. The hotel is located three blocks down on the right side.
- **From San Jose** – Take Highway 101 North and exit onto Embarcadero Road West. Proceed approximately two miles and turn right onto El Camino Real. The hotel is located three blocks down and on the right side
- **From the East Bay** – Take the San Francisco Bay Bridge (I-80) or the San Mateo Bridge (Hwy 82) Westbound. Then follow signs to Highway 101 South and exit onto Embarcadero Road West. Proceed approximately two miles and turn right onto El Camino Real. The hotel is located three blocks down on the right side.

Seminar Agenda and Syllabus Information Registration and breakfast begin at **7:30 a.m.** in the **Cypress Room**. Please check signage for any last minute room changes.
The Emerging Therapies seminar is a paperless program. The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet device or personal computer. Instructions to download the *App* will be provided to participants in advance of the seminar. WiFi will be available without charge.

7:30 am	Registration, Continental Breakfast & View Exhibits
8:00 am	Opening Comments and Pre-Test
8:20 am	End Stage Liver Disease: Treatment, Managing Complications and Transplant <ul style="list-style-type: none"> • Staging, workup, and diagnosis of cirrhosis • Medical care of the patient with end stage liver disease Liver Transplantation <ul style="list-style-type: none"> • Listing criteria, MELD scores, Exceptions and the transplant process Case Study 1 – Cirrhosis and Encephalopathy
9:25 am	Hepatocellular Carcinoma (HCC) <ul style="list-style-type: none"> • Screening diagnostic serum assays and imaging tests • Diagnosis without histology • Treatment and management options: Ablation, TACE and Surgery
10:00 am	Break & View Exhibits
10:15 am	Hepatocellular Carcinoma: New Systemic Treatment Options <ul style="list-style-type: none"> • Current FDA-Approved Therapies • New chemotherapy regimens in development and testing

	<ul style="list-style-type: none"> Immunotherapy as the new MoA for HCC Case Study 2 – Diagnosis and Treatment of Hepatocellular Carcinoma
11:00 am	Primary Sclerosing Cholangitis (PSC) <ul style="list-style-type: none"> Epidemiology Ursodiol and Antibiotic Treatments Predicting outcomes and Improving Survival
11:25 am	New Treatments for PBC <ul style="list-style-type: none"> Causes and Markers of PBC Treatment management Ursodeoxycholic Acid (UDCA) and Obeticholic Acid
12:00 pm	Hosted Luncheon and Educational Session “LAL-D: Lysosomal Acid Lipase Deficiency- Implementing Rule-out testing in patients with elevated ALT and LDL-C
12:45 pm	Coffee and Dessert & View Exhibits
1:00 pm	The Best Use of Non-Invasive Imaging for Fibrosis Assessment <ul style="list-style-type: none"> Technologies, Procedures and Outcomes
1:30 pm	NAFLD, LAL-D and NASH <ul style="list-style-type: none"> Epidemiology, Demographics and Diagnosis Treatment options for thrombocytopenia; including alternatives to platelet transfusion. Treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D) causing adult Fatty Liver Disease
2:15 pm	Break & View Exhibits
2:30 pm	NASH Treatments in Practice and in Development <ul style="list-style-type: none"> Current therapies for NASH Life style changes as a therapy Drugs in clinical development for NASH Case Study 3 - NASH Diagnosis and Treatment
3:30 pm	Post-test and Wrap-Up <ul style="list-style-type: none"> Session adjourns at 3:45pm

Attendee Cancellation, Substitution, Refund

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is **received in writing no later than seven days prior** to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

Recording and Photography

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

Attendance Policies

Guest Attendance

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

Conference Modification or Cancellation

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course’s schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

CME Information

Physicians (MD/DO) - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **6.0 AMA PRA Category 1 Credit(s)**TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses - This program has been approved by the Kentucky Board of Nursing for 7.1 continuing education credits through University of Louisville Hospital, provider number 4-0068-7-18-1030. The Kentucky Board of Nursing approval of an individual nursing education provide does not constitute endorsement of program content.

Nurse Practitioners and Physician Assistants - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)TM organizations accredited by ACCME.

**Your Seminar
Faculty**



R. TODD FREDERICK, MD

Dr. Todd Frederick is a transplant Hepatologist with the San Francisco Center for Liver Disease at California Pacific Medical Center. He currently serves as Fellowship Director for Transplant Hepatology as well as the Director of Quality and Clinical Protocols for the Division.

Dr. Frederick was appointed by San Francisco Mayor Gavin Newsom to serve on the Hepatitis C Task Force in 2009 where he assisted in drafting recommendations to the City for an approach to the HCV epidemic.

Dr. Frederick is a member of several professional societies, including the American Gastroenterological Association, the American Association for the Study of Liver Diseases, and the European Association for the Study of the Liver.



DANIELLE BRANDMAN, MD, MAS

Dr. Danielle Brandman is a hepatologist, who has expertise in treating patients with nonalcoholic fatty liver disease and patients needing liver transplants. She also treats conditions such as cirrhosis, primary biliary cholangitis, liver cancer, , and primary sclerosing cholangitis. She serves as the hepatologist for the UCSF Polycystic Kidney Disease Center of Excellence. Dr. Brandman earned a medical degree at the New Jersey Medical School of Rutgers University, and completed an internal medicine internship and residency at UCSF. She also completed fellowships in gastroenterology and transplant hepatology. Brandman is an associate professor of medicine at UCSF. Dr. Brandman serves on the Medical Advisory Committee for the American Liver Foundation Northern California Chapter.



MARICE THOMAS, APRN, FNP-C

Marice is a Family Nurse Practitioner, Board Certified through American Nurses Credentialing Center. She graduated with Associate Degree in Nursing from College of the Redwoods in 1977, Bachelor's Degree in Nursing from CSU Dominguez Hills in 1987 and Master's Degree in Nursing- Family Nurse Practitioner from Sonoma State University in 1999.

Marice's initial practice area was in Primary Care with a focus on Family Practice. In 2005, she began an emphasis and training in Hepatology which was directed toward the treatment and management of Hepatitis C. This was in rural Northern California in association with Physician Foundation at California Pacific Medical Center.

Since 2007, Marice works in collaboration with Hepatologists and other providers at Sutter Pacific Medical Foundation and California Pacific Medical Center Liver Transplant Program.
